Vertex Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX PHARMS INC, and when can generic versions of VERTEX PHARMS INC drugs launch?
VERTEX PHARMS INC has six approved drugs.
There are forty-eight US patents protecting VERTEX PHARMS INC drugs.
There are six hundred and sixty-six patent family members on VERTEX PHARMS INC drugs in forty-seven countries and sixty-eight supplementary protection certificates in nineteen countries.
Summary for Vertex Pharms Inc
| International Patents: | 666 |
| US Patents: | 48 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 6 |
Drugs and US Patents for Vertex Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | 10,793,547 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Vertex Pharms Inc | SYMDEKO (COPACKAGED) | ivacaftor; ivacaftor, tezacaftor | TABLET;ORAL | 210491-001 | Feb 12, 2018 | RX | Yes | Yes | 7,495,103 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | 11,639,347 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-002 | Aug 7, 2018 | RX | Yes | Yes | 8,653,103 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-004 | May 3, 2023 | RX | Yes | No | 8,629,162 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Vertex Pharms Inc Drugs
Supplementary Protection Certificates for Vertex Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1773816 | 1590036-8 | Sweden | ⤷ Sign Up | PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/12/782/001 20120725 |
| 2404919 | 2016/018 | Ireland | ⤷ Sign Up | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5- YL)CYCLOPROPANECARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (LUMACAFTOR), OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR AN ESTER PRODRUG THEREOF; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
| 3170818 | SPC/GB20/041 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF (A) 3-(6-(1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (I.E. LUMACAFTOR) AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE (I.E. IVACAFTOR) OR A PHARMACEUT; REGISTERED: UK EU/1/15/1059(NI) 20151124; UK PLGB 22352/0004 20151124 |
| 2826776 | 13/2021 | Austria | ⤷ Sign Up | PRODUCT NAME: KOMBINATION VON (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANCARBOXAMID UND (B) N-(5-HYDROXY-2,4-DI-TERT-BUTYLPHENYL)-4-OXO-1H-CHINOLIN-3-CARBOXAMID; REGISTRATION NO/DATE: EU/1/18/1306 (MITTEILUNG) 20181106 |
| 3170818 | 2020C/005 | Belgium | ⤷ Sign Up | PRODUCT NAME: ORKAMBI (LUMACAFTOR + IVACAFTOR); AUTHORISATION NUMBER AND DATE: EU/1/15/1059 20151124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
